|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
361,116 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bonstein Sara |
Chief Financial Officer |
|
2016-09-30 |
4 |
D |
$10.69 |
$460 |
D/D |
(43) |
81,577 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-09-30 |
4 |
A |
$10.69 |
$2,042 |
D/D |
191 |
81,620 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-09-30 |
4 |
D |
$10.69 |
$535 |
D/D |
(50) |
302,660 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-09-30 |
4 |
A |
$10.69 |
$3,784 |
D/D |
354 |
302,710 |
|
- |
|
Mayes Gregory T. |
Chief Business Officer |
|
2016-09-30 |
4 |
D |
$10.69 |
$481 |
D/D |
(45) |
122,249 |
|
- |
|
Mayes Gregory T. |
Chief Business Officer |
|
2016-09-30 |
4 |
A |
$10.69 |
$2,181 |
D/D |
204 |
122,294 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-08-31 |
4 |
D |
$11.53 |
$530 |
D/D |
(46) |
302,356 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-08-31 |
4 |
A |
$11.53 |
$3,782 |
D/D |
328 |
302,402 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-08-31 |
4 |
D |
$11.53 |
$484 |
D/D |
(42) |
122,090 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-08-31 |
4 |
A |
$11.53 |
$2,191 |
D/D |
190 |
122,132 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-08-31 |
4 |
D |
$11.53 |
$334 |
D/D |
(29) |
123,197 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-08-31 |
4 |
A |
$11.53 |
$2,271 |
D/D |
197 |
123,226 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-08-31 |
4 |
D |
$11.53 |
$461 |
D/D |
(40) |
81,429 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-08-31 |
4 |
A |
$11.53 |
$2,041 |
D/D |
177 |
81,469 |
|
- |
|
Sidransky David |
Director |
|
2016-08-09 |
4 |
S |
$14.85 |
$169,349 |
D/D |
(11,404) |
80,355 |
|
- |
|
Berman Richard J |
Director |
|
2016-08-09 |
4 |
S |
$15.67 |
$246,975 |
D/D |
(15,761) |
50,669 |
|
- |
|
Sidransky David |
Director |
|
2016-08-08 |
4 |
S |
$15.17 |
$172,999 |
D/D |
(11,404) |
91,759 |
|
- |
|
Berman Richard J |
Director |
|
2016-08-08 |
4 |
S |
$15.21 |
$273,780 |
D/D |
(18,000) |
66,430 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-07-29 |
4 |
D |
$8.34 |
$484 |
D/D |
(58) |
121,942 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-07-29 |
4 |
A |
$8.34 |
$2,185 |
D/D |
262 |
122,000 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-07-29 |
4 |
D |
$8.34 |
$4,687 |
D/D |
(562) |
310,341 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-07-29 |
4 |
A |
$8.34 |
$9,449 |
D/D |
1,133 |
310,903 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-07-29 |
4 |
D |
$8.34 |
$959 |
D/D |
(115) |
125,834 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-07-29 |
4 |
A |
$8.34 |
$2,277 |
D/D |
273 |
125,949 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-07-29 |
4 |
D |
$8.34 |
$450 |
D/D |
(54) |
81,292 |
|
- |
|
586 Records found
|
|
Page 6 of 24 |
|
|